Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9048269,elimination half-life,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),min,117.5,47186,DB06800,Methylnaltrexone
,9048269,clearance,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),[l] / [h],38.8,47187,DB06800,Methylnaltrexone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,101.3,71142,DB06800,Methylnaltrexone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,82.5,71143,DB06800,Methylnaltrexone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],538,71144,DB06800,Methylnaltrexone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],675,71145,DB06800,Methylnaltrexone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.5,71146,DB06800,Methylnaltrexone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.9,71147,DB06800,Methylnaltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],93.5,71726,DB06800,Methylnaltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71727,DB06800,Methylnaltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],364,71728,DB06800,Methylnaltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],88.8,71729,DB06800,Methylnaltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],181,71730,DB06800,Methylnaltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],357,71731,DB06800,Methylnaltrexone
,28776489,t1/2,The t1/2 of MNTX was about 7.7 h.,Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,7.7,71732,DB06800,Methylnaltrexone
,28776489,Cmax,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71733,DB06800,Methylnaltrexone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71734,DB06800,Methylnaltrexone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71735,DB06800,Methylnaltrexone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71736,DB06800,Methylnaltrexone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71737,DB06800,Methylnaltrexone
,28776489,MRT0-∞,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,3.56,71738,DB06800,Methylnaltrexone
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,41,94855,DB06800,Methylnaltrexone
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,45.5,94856,DB06800,Methylnaltrexone
,2618077,elimination phase,with a longer elimination phase between 238 and 1320 min.,"Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618077/),min,238 and 1320,96631,DB06800,Methylnaltrexone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,85,167046,DB06800,Methylnaltrexone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,155,167047,DB06800,Methylnaltrexone
,11752106,transit time,"After 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 +/- 41.0 min.",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,110,167048,DB06800,Methylnaltrexone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,98,167049,DB06800,Methylnaltrexone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,140,167050,DB06800,Methylnaltrexone
,11752106,transit time,"After 0.3 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 108 +/- 59.6 min (P < 0.05 compared with placebo plus morphine).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,108,167051,DB06800,Methylnaltrexone
,16740093,steady-state volume of distribution,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg],244.6,195175,DB06800,Methylnaltrexone
,16740093,t1/2,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),min,47.04,195176,DB06800,Methylnaltrexone
,16740093,clearance,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg·min],11.43,195177,DB06800,Methylnaltrexone
,23327357,Tmax,"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209595,DB06800,Methylnaltrexone
,23327357,C(max),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],1083.7,209596,DB06800,Methylnaltrexone
,23327357,T(½),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,496,209597,DB06800,Methylnaltrexone
,23327357,T(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209598,DB06800,Methylnaltrexone
,23327357,C(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],448.4,209599,DB06800,Methylnaltrexone
,23327357,T(½),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,259,209600,DB06800,Methylnaltrexone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],5758.2,209601,DB06800,Methylnaltrexone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],1405.9,209602,DB06800,Methylnaltrexone
,23327357,relative bioavailability,"Thus, the relative bioavailability after the oral administration of MNTX-PC was 410% compared to that of control.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),%,410,209603,DB06800,Methylnaltrexone
,12401350,flow-rate,"The procedure was performed using a Phenomenex Prodigy ODS-2, 5 microm, 150x3.2 mm analytical column and 50 mM potassium acetate buffer, with 11% methanol as organic modifier at pH* 4.5 at a flow-rate of 0.5 ml/min.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ml] / [min],0.5,268919,DB06800,Methylnaltrexone
,12401350,detection potential,The detection potential was 700 mV.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),m,700,268920,DB06800,Methylnaltrexone
,12401350,limit of quantification (LOQ),"The lower limit of detection (LOD) and limit of quantification (LOQ) were found to be 2.0 and 5.0 ng/ml, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],5.0,268921,DB06800,Methylnaltrexone
,12401350,Recovery,Recovery of the drug from plasma was in the region of 94%.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),%,94,268922,DB06800,Methylnaltrexone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],110,268923,DB06800,Methylnaltrexone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],287,268924,DB06800,Methylnaltrexone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,16.7,268925,DB06800,Methylnaltrexone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,20.0,268926,DB06800,Methylnaltrexone
